SDC1 and acute kidney injury: Angiopoietin-2 (AUC = 0.72, 95% CI 0.65–0.79, p < 0.001), endocan (AUC = 0.61, 95% CI 0.54–0.69, p = 0.004), sVE-cadherin (AUC = 0.62, 95% CI 0.55–0.70, p = 0.002), and syndecan-1 (AUC = 0.64, 95% CI 0.57–0.72, p < 0.001) all had moderate discriminative powers for severe AKI within the four study days.